Matches in SemOpenAlex for { <https://semopenalex.org/work/W2593231312> ?p ?o ?g. }
- W2593231312 endingPage "e213" @default.
- W2593231312 startingPage "e205" @default.
- W2593231312 abstract "Background Tenofovir alafenamide is a prodrug that reduces tenofovir plasma concentrations by 90% compared with tenofovir disoproxil fumarate, thereby decreasing bone and renal risks. The coformulation of rilpivirine, emtricitabine, and tenofovir alafenamide has recently been approved, and we aimed to investigate the efficacy, safety, and tolerability of switching to this regimen compared with remaining on coformulated efavirenz, emtricitabine, and tenofovir disoproxil fumarate. Methods In this randomised, double-blind, placebo-controlled, non-inferiority trial, HIV-1-infected adults were enrolled at 120 hospitals and outpatient clinics in eight countries in North America and Europe. Participants were virally suppressed (HIV-1 RNA <50 copies per mL) on efavirenz, emtricitabine, and tenofovir disoproxil fumarate for at least 6 months before enrolment and had creatinine clearance of at least 50 mL/min. Participants were randomly assigned (1:1) to receive a single-tablet regimen of rilpivirine (25 mg), emtricitabine (200 mg), and tenofovir alafenamide (25 mg) or to continue a single-tablet regimen of efavirenz (600 mg), emtricitabine (200 mg), and tenofovir disoproxil fumarate (300 mg), with matching placebo. Investigators, participants, study staff, and those assessing outcomes were masked to treatment group. The primary endpoint was the proportion of participants with plasma HIV-1 RNA of less than 50 copies per mL at week 48 (assessed by the US Food and Drug Administration snapshot algorithm), with a prespecified non-inferiority margin of 8%. This study was registered with ClinicalTrials.gov, number NCT02345226. Findings Between Jan 26, 2015, and Aug 27, 2015, 875 participants were randomly assigned and treated (438 with rilpivirine, emtricitabine, and tenofovir alafenamide and 437 with efavirenz, emtricitabine, tenofovir disoproxil fumarate). Viral suppression at week 48 was maintained in 394 (90%) of 438 participants assigned to the tenofovir alafenamide regimen and 402 (92%) of 437 assigned to the tenofovir disoproxil fumarate regimen (difference −2·0%, 95·001% CI −5·9 to 1·8), demonstrating non-inferiority. 56 (13%) of 438 in participants in the rilpivirine, emtricitabine, and tenofovir alafenamide group experienced treatment-related adverse events compared with 45 (10%) of 437 in the efavirenz, emtricitabine, and tenofovir disoproxil fumarate group. Interpretation Switching to rilpivirine, emtricitabine, and tenofovir alafenamide from efavirenz, emtricitabine, and tenofovir disoproxil fumarate was non-inferior in maintaining viral suppression and was well tolerated at 48 weeks. These findings support guidelines recommending tenofovir alafenamide-based regimens, including coformulation with rilpivirine and emtricitabine, as initial and ongoing treatment for HIV-1 infection. Funding Gilead Sciences." @default.
- W2593231312 created "2017-03-16" @default.
- W2593231312 creator A5001632717 @default.
- W2593231312 creator A5003323389 @default.
- W2593231312 creator A5009725573 @default.
- W2593231312 creator A5028586840 @default.
- W2593231312 creator A5033466901 @default.
- W2593231312 creator A5036075930 @default.
- W2593231312 creator A5038105767 @default.
- W2593231312 creator A5042040728 @default.
- W2593231312 creator A5046238828 @default.
- W2593231312 creator A5053506132 @default.
- W2593231312 creator A5063307423 @default.
- W2593231312 creator A5065768749 @default.
- W2593231312 creator A5065924768 @default.
- W2593231312 creator A5069170911 @default.
- W2593231312 creator A5073100933 @default.
- W2593231312 creator A5089221765 @default.
- W2593231312 creator A5089993955 @default.
- W2593231312 creator A5091909943 @default.
- W2593231312 date "2017-05-01" @default.
- W2593231312 modified "2023-10-18" @default.
- W2593231312 title "Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study" @default.
- W2593231312 cites W1971384013 @default.
- W2593231312 cites W1979080264 @default.
- W2593231312 cites W2017605567 @default.
- W2593231312 cites W2036350240 @default.
- W2593231312 cites W2054487205 @default.
- W2593231312 cites W2057714331 @default.
- W2593231312 cites W2066291317 @default.
- W2593231312 cites W2067000782 @default.
- W2593231312 cites W2070237659 @default.
- W2593231312 cites W2075474943 @default.
- W2593231312 cites W2076175848 @default.
- W2593231312 cites W2115179084 @default.
- W2593231312 cites W2143166782 @default.
- W2593231312 cites W2149185709 @default.
- W2593231312 cites W2186174256 @default.
- W2593231312 cites W2196190612 @default.
- W2593231312 cites W2301510887 @default.
- W2593231312 cites W2397692736 @default.
- W2593231312 cites W2593423583 @default.
- W2593231312 doi "https://doi.org/10.1016/s2352-3018(17)30032-2" @default.
- W2593231312 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28259776" @default.
- W2593231312 hasPublicationYear "2017" @default.
- W2593231312 type Work @default.
- W2593231312 sameAs 2593231312 @default.
- W2593231312 citedByCount "42" @default.
- W2593231312 countsByYear W25932313122017 @default.
- W2593231312 countsByYear W25932313122018 @default.
- W2593231312 countsByYear W25932313122019 @default.
- W2593231312 countsByYear W25932313122020 @default.
- W2593231312 countsByYear W25932313122021 @default.
- W2593231312 countsByYear W25932313122022 @default.
- W2593231312 countsByYear W25932313122023 @default.
- W2593231312 crossrefType "journal-article" @default.
- W2593231312 hasAuthorship W2593231312A5001632717 @default.
- W2593231312 hasAuthorship W2593231312A5003323389 @default.
- W2593231312 hasAuthorship W2593231312A5009725573 @default.
- W2593231312 hasAuthorship W2593231312A5028586840 @default.
- W2593231312 hasAuthorship W2593231312A5033466901 @default.
- W2593231312 hasAuthorship W2593231312A5036075930 @default.
- W2593231312 hasAuthorship W2593231312A5038105767 @default.
- W2593231312 hasAuthorship W2593231312A5042040728 @default.
- W2593231312 hasAuthorship W2593231312A5046238828 @default.
- W2593231312 hasAuthorship W2593231312A5053506132 @default.
- W2593231312 hasAuthorship W2593231312A5063307423 @default.
- W2593231312 hasAuthorship W2593231312A5065768749 @default.
- W2593231312 hasAuthorship W2593231312A5065924768 @default.
- W2593231312 hasAuthorship W2593231312A5069170911 @default.
- W2593231312 hasAuthorship W2593231312A5073100933 @default.
- W2593231312 hasAuthorship W2593231312A5089221765 @default.
- W2593231312 hasAuthorship W2593231312A5089993955 @default.
- W2593231312 hasAuthorship W2593231312A5091909943 @default.
- W2593231312 hasConcept C126322002 @default.
- W2593231312 hasConcept C142462285 @default.
- W2593231312 hasConcept C142724271 @default.
- W2593231312 hasConcept C159047783 @default.
- W2593231312 hasConcept C197934379 @default.
- W2593231312 hasConcept C204787440 @default.
- W2593231312 hasConcept C27081682 @default.
- W2593231312 hasConcept C2778375690 @default.
- W2593231312 hasConcept C2778723075 @default.
- W2593231312 hasConcept C2779778239 @default.
- W2593231312 hasConcept C2780524789 @default.
- W2593231312 hasConcept C2781413609 @default.
- W2593231312 hasConcept C2781432083 @default.
- W2593231312 hasConcept C2911190787 @default.
- W2593231312 hasConcept C2993143319 @default.
- W2593231312 hasConcept C3013748606 @default.
- W2593231312 hasConcept C71924100 @default.
- W2593231312 hasConcept C98274493 @default.
- W2593231312 hasConceptScore W2593231312C126322002 @default.
- W2593231312 hasConceptScore W2593231312C142462285 @default.
- W2593231312 hasConceptScore W2593231312C142724271 @default.
- W2593231312 hasConceptScore W2593231312C159047783 @default.
- W2593231312 hasConceptScore W2593231312C197934379 @default.
- W2593231312 hasConceptScore W2593231312C204787440 @default.